Which stool test is best for colorectal cancer detection?

With the development of faecal immunochemical tests (FIT), many breathed a sigh of relief. The non-invasive tool promises to accurately detect blood in the stool, often an early sign of cancer, allowing patients to skip the colonoscopy if test results are negative. What's more, the sample can be collected in the privacy of one's own home with no dietary or medical restrictions. But just how accurate are these new FIT tests?

Researchers develop novel immunotherapy to target colorectal cancer

A Yale-led research team has developed an antibody that blocks tumours in animal models of colorectal cancer. If the findings are confirmed in clinical trials, the antibody-based treatment could become an effective weapon against colorectal cancer, and possibly other cancers, that resist current immunotherapies.

Studies report bacteria play critical role in driving colon cancers

Patients with an inherited form of colon cancer have two bacterial species that collaborate to encourage development of the disease, and the same species have been found in people who develop a sporadic form of colon cancer, a study led by a Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy research team has report.

Specific diets prevent colorectal cancer in high-risk groups

It is known that factors such as diet and intestinal inflammation play an important role in colorectal cancer. However, direct links between nutrients, inflammation and colorectal cancer are poorly described, according to researchers at the Spanish National Cancer Research Centre (CNIO). New research by CNIO has discovered that the amount of protein consumed may be an important factor in the prevention of colorectal cancer in different risk groups.

Twenty percent of young colon cancer patients have genetic link

Research from the University of Michigan (U-M) may offer some insight into how colon cancer develops and how to prevent further cancers, after investigators reported that 20 percent of young people diagnosed with colorectal cancer have an inherited genetic abnormality that predisposes to its development - a percentage exponentially higher than those diagnosed over age 50. More than half of them do not have clinical or family histories that would typically indicate the need for genetic testing.

Testing for specific proteins improves sensitivity of stool-based CC screening

Testing for novel protein biomarkers in stool finds significantly more colorectal cancers (CRC) and advanced adenomas (precursors to cancer) compared to testing for haemoglobin alone - proteins can be detected in a small sample of the faecal immunochemical test (FIT), which suggests that they can be applied in population screening.

Insurance coverage differences accounts for disparity in colorectal cancer survival rate between black vs white patients

Health insurance coverage differences account for nearly one-half of the black-white survival disparity in colorectal cancer patients, according to a study by researchers from the American Cancer Society and the Dana-Farber Cancer Institute at Harvard Medical School. The study, ‘Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer’, published in Gastroenterology, reinforces the importance of equitable health insurance coverage to mitigate the black-white survival disparity in colorectal cancer.